Summary
Assessing the level of residual disease in leukemia is vital for evaluating patients’ response to treatment and for identifying those at high risk of relapse. This should enable early preemptive intervention to prevent the onset of hematological relapse in those patients. One of the most common translocations in acute myeloid leukemia (AML) is the t(8;21). t(8;21) AML is characterized by a relatively good prognosis. This chapter discusses both qualitative and quantitative (real-time quantitative reverse-transcription polymerase chain reaction [RQ-PCR]) protocols for the diagnosis and minimal residual disease (MRD) monitoring in t(8;21) AML. It also discusses the importance of choosing appropriate controls for each assay. The chapter provides a simple equation for assessing the sensitivity/reliability of RQ-PCR assays, which enables scientists to assess the accuracy and reliability of their data.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Raimondi S. C., Kalwinsky D. K., Hayashi Y., Behm F. G., Mirro J. Jr., and Williams D. L. (1989) Cytogenetics of childhood acute nonlymphocytic leukemia. Cancer Genet. Cytogenet. 40, 13–27.
Rowley J. D. (1990) Recurring chromosome abnormalities in leukemia and lymphoma. Semin. Hematol. 27, 122–136.
Erickson P., Gao J., Chang K. S., et al. (1992) Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ ETO, with similarity to Drosophila segmentation gene, runt. Blood 80, 1825–1831.
Gabert J., Beillard E., van der Velden V. H. J., et al. (2003) Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia A Europe Against Cancer Program. Leukemia 17, 2318–2357.
Chomczynski P. and Sacchi N. (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156–159.
Nucifora G., Larson R. A., and Rowley J. D. (1993) Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 82, 712–715.
Kusec R., Laczika K., Knobl P., et al. (1994) AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 8, 735–739.
Saunders M. J., Tobal K., and Liu Yin J. A. (1994) detection of t(8;21) by reverse transcriptase polymerase chain reaction in patients in remission of acute myeloid leukemia type M2 after chemotherapy or bone marrow transplantation. Leuk. Res. 18, 891–895.
Morschhauser F., Cayuela J. M., Martini S., et al. (2000) Evaluation of minimal residual disease using reverse transcriptase polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicentre study of 51 patients. J. Clin. Oncol. 18, 788–794.
Lion T. and Kidd V. (chairmen). (1998) Debate round-table: appropriate controls for RT-PCR. Leukemia 12, 1983–1993.
Tobal K., Newton J., Macheta M., et al. (2000) Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 95, 815–819.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Humana Press Inc.
About this protocol
Cite this protocol
Tobal, K., Liu Yin, J.A. (2006). Diagnosis and Monitoring of AML1-MTG8 (ETO)-Positive Acute Myeloid Leukemia by Qualitative and Real-Time Quantitative RT-PCR. In: Iland, H., Hertzberg, M., Marlton, P. (eds) Myeloid Leukemia. Methods In Molecular Medicine™, vol 125. Humana Press. https://doi.org/10.1385/1-59745-017-0:149
Download citation
DOI: https://doi.org/10.1385/1-59745-017-0:149
Publisher Name: Humana Press
Print ISBN: 978-1-58829-485-2
Online ISBN: 978-1-59745-017-1
eBook Packages: Springer Protocols